0
0

BENEFIT Act of 2023

3/14/2024, 2:03 AM

Congressional Summary of S 526

Better Empowerment Now to Enhance Framework and Improve Treatments Act of 2023 or the BENEFIT Act of 2023

This bill requires the Food and Drug Administration (FDA) to consider relevant patient experience data in the risk-benefit assessment framework used in the process for approving new drugs.

After a new drug application has been approved, the FDA's public statement about how it used patient experience data shall include a description of how such data was considered in the risk-benefit assessment framework.

Current Status of Bill S 526

Bill S 526 is currently in the status of Bill Introduced since February 16, 2023. Bill S 526 was introduced during Congress 118 and was introduced to the Senate on February 16, 2023.  Bill S 526's most recent activity was Read twice and referred to the Committee on Health, Education, Labor, and Pensions. as of February 16, 2023

Bipartisan Support of Bill S 526

Total Number of Sponsors
1
Democrat Sponsors
0
Republican Sponsors
1
Unaffiliated Sponsors
0
Total Number of Cosponsors
4
Democrat Cosponsors
1
Republican Cosponsors
3
Unaffiliated Cosponsors
0

Policy Area and Potential Impact of Bill S 526

Primary Policy Focus

Health

Alternate Title(s) of Bill S 526

BENEFIT Act of 2023
BENEFIT Act of 2023
Better Empowerment Now to Enhance Framework and Improve Treatments Act of 2023
A bill to strengthen the use of patient-experience data within the benefit-risk framework for approval of new drugs.

Comments